Targeted Therapy Market Analysis By Type(Small Molecule Medicines, Monoclonal Antibodies), By Application(Breast Cancer, Colorectal Cancer, Leukaemia, Lung Cancer, Lymphoma, Renal Cancer), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) & Forecast
- PUBLISHED ON
- 24/03/2023
- NO OF PAGES
- 260
- CATEGORY
- Healthcare & Life Sciences
The growth in incidence of cancers such as breast, lung, and leukaemia has fuelled the demand for targeted therapies. Cancer is a prominent cause of death across the world. It is more dominant in developed and emerging nations. As per the International Agency for Research on Cancer, one in five persons grows cancer throughout their lifetime, and one in eight men, and one in 11 women succumbs to the ailment. Tobacco smoking, changing lifestyle, pollution, and spread of carcinogens and carcinogenic infections such as H. Pylori, HPV, and HCV have augmented the incidence rate of cancer across the world.
As per the International Agency for Research on Cancer (IARC), a projected 19.3 million new cancer cases were documented in 2020 and approximately 10 million individuals died from cancer-related reasons. The global burden is projected to upsurge to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040, principally due to elderly population. Targeted therapy has confirmed to offer hopeful therapeutic results across a broad range of cancers and is gradually used in healthcare facilities. Therefore, high prevalence and growth in incidence rate of cancer around the globe is a major aspect anticipated to boost the growth of the global targeted therapy market during the forecast period.
COVID-19 causes several challenges to cancer practice, specially to ensure steadiness of treatment throughout this period. It has considerably affected healthcare systems and markets in a short timeframe. Numerous diagnostic & research centres had to slow their action owing to public health events. Thus, the developing cancer research was affected owing to the COVID-19. Though, targeted therapy is being assessed in COVID-19 treatment. Thus, by boosting clinicians to pursue targeted therapy agents through the pandemic is likely anticipated to create opportunity during the forecasted period.
Type Insights
Based on type, the monoclonal antibodies segment accounted largest revenue share in 2021. The monoclonal antibodies are the most active drugs used in the treatment of several types of cancer. It is safer and has lesser toxicity as linked to that of the customary chemotherapy used in the cancer treatment. Hence, the reduced side effect along with the effective treatment of cancer has boosted the growth of this segment.
The small molecule segment is anticipated to be the fastest-growing segment throughout the forecast period. The small molecule drugs are very much active in aiming the specific cancer cells. The small molecule is receiving traction in the established markets for the treatment of malignancies. In 2020, the FDA accepted around 89 anti-tumor small molecule drugs. Thus, this section is anticipated to drive the growth of the targeted therapy market during the forecasted period.
Application Insights
Breast cancer segment expects to register the highest CAGR in the forecasted period. The major factors fuelling the market's growth are the growing prevalence of breast cancer, rising investment by the businesses in research and development, and developments in cancer biology and pharmacology promoting drug development. The higher incidence and prevalence rate of breast cancer globally is a major factor driving the market's growth. As per the American Cancer Society, 2021, breast cancer has exceeded lung cancer as the most commonly diagnosed cancer and the fifth leading cause of death from cancer across the globe. As per the statistics published by the National Breast Cancer Foundation, in 2021, it is projected that 281,550 new cases of invasive breast cancer and 49,290 new cases of non-invasive (in situ) breast cancer will be identified in women in the United States. Moreover, around 63% of breast cancer patients have been detected with local-stage breast cancer, 27% with regional stage, and 6% with a distant (metastatic) ailment. As per the statistics printed by Cancer Australia, in 2021, it was projected that 20,030 new cases of breast cancer were detected in Australia (164 males and 19,866 females).
Region Insights
North America dominated the global targeted therapy market in 2021, followed by Europe. The U.S. led the targeted therapy market in North America in 2021, owing to the presence of major players, acceptance of targeted therapeutics monoclonal antibodies, and satisfactory reimbursement policies. This, in turn, is projected to increase the market in the region.
The targeted therapy market in Asia Pacific is likely to grow at a high CAGR from 2021 to 2030. The growth of the market in the region can be accredited to the acceptance of new targeted therapeutic drugs, growth in awareness about several oncological disorders, upsurge in healthcare expenditure, and great penetration of research activities through the region.
Key Companies Insights
The market for targeted therapy is moderately competitive. With the rising applications of Targeted therapy, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Targeted therapy market, ultimately boosting the market growth.
• Amgen Inc.
• GlaxoSmithKline plc
• Sanofi
• Takeda Pharmaceutical Company Limited
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• AstraZeneca
• Seagen Inc.
• Bayer AG
• Bristol Myers Squibb
• Other players
Some of the Recent Developments:
• In May 2021, Xilio Therapeutics entered into a clinical trial collaboration and supply agreement with Merck outside the U.S. and Canada, to estimate XTX101, Xilio’s caused tumor-selective Fc-enhanced, anti-CTLA-4 monoclonal antibody (mAb) product candidate, in mixture with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy.
• In March 2020, Sanofi’s Sarclisa was approved along with pomalidomide and dexamethasone in the U.S. for the treatment of grown-ups with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies, comprising lenalidomide and a proteasome inhibitor, and by the European Commission in June 2020. Sarclisa has currently been launched in the U.S., Austria, Japan, Switzerland, Canada, and the U.K.
Segments
By Type
• Small Molecule Medicines
o Tyrosine Kinase Inhibitors
o mTOR Inhibitors
o PARP Inhibitors
• Monoclonal Antibodies
o Angiogenesis Inhibitors
o HER-2 Targeted Agents
o Anti-CD20 Monoclonal Antibodies
By Application
• Breast Cancer
• Colorectal Cancer
• Leukaemia
• Lung Cancer
• Lymphoma
• Renal Cancer
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt
Quality Assurance Process
- We Market Research’s Quality Assurance program strives to deliver superior value to our clients.
We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.
Market Research Process
We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.
To mitigate risks that can impact project success, we deploy the follow project delivery best practices:
- Project kickoff meeting with client
- Conduct frequent client communications
- Form project steering committee
- Assign a senior SR executive as QA Executive
- Conduct internal editorial & quality reviews of project deliverables
- Certify project staff in SR methodologies & standards
- Monitor client satisfaction
- Monitor realized value post-project
Case Study- Automotive Sector
One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).
Solution
The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research
The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.
Market Estimates and Forecast
In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.
Case Study- ICT Sector
Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.
Business Solution
An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.
Conclusion
The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.
}})
Select a license type that suits your business needs
US $4250
Only Four Thousand Two Hundred Fifty US dollar
- 1 User access
- 15% Additional Free Customization
- Free Unlimited post-sale support
- 100% Service Guarantee until achievement of ROI
US $5250
Only Five Thousand Two Hundred Fifty US dollar
- 5 Users access
- 25% Additional Free Customization
- Access Report summaries for Free
- Guaranteed service
- Dedicated Account Manager
- Discount of 20% on next purchase
- Get personalized market brief from Lead Author
- Printing of Report permitted
- Discount of 20% on next purchase
- 100% Service Guarantee until achievement of ROI
US $6250
Only Six Thousand Two Hundred Fifty US dollar
- Unlimited User Access
- 30% Additional Free Customization
- Exclusive Previews to latest or upcoming reports
- Discount of 30% on next purchase
- 100% Service Guarantee until achievement of ROI